Santhera Pharmaceuticals
http://www.santhera.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Santhera Pharmaceuticals
Biliary Tract Cancer Fail Is Another Blow for Merck KGaA/GSK's Bintrafusp
Less than two months after bintrafusp failed to beat Merck & Co's blockbuster Keytruda in a Phase III NSCLC trial, Merck KGaA's bispecific fusion protein partnered with GSK has disappointed in a mid-stage study for biliary tract cancer.
Resetting After Your Lead Drug Fails
Becoming a first-time CEO of a biotech company in 2020 meant dealing with unexpected challenges without any instruction book to follow. Santhera Pharmaceuticals’ Dario Eklund not only had COVID-19 upheaval to manage, but also a late-stage trial failure, a virtual financing and a new plan for the company to sell to stakeholders.
BioMarin Pulls EU Hemophilia Gene Therapy Filing, But Is Not Giving Up
BioMarin plans to resubmit its marketing application for Roctavian to the European Medicines Agency.
Santhera Pulls EU Filing For Failed DMD Candidate
Swiss company Santhera's lengthy and problem-laden journey to repurpose its already marketed idebenone for use in Duchenne Muscular Dystrophy has ended in failure. The company has withdrawn its EU filing for the product following its announcement that it was halting development.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Oy Juvantia Pharma Ltd